CTX310: durable lipid biomarkers are not lifespan evidence
A phase 1a report described one-year durability of ANGPTL3 and lipid reductions after CTX310. The assessment notes that the abstract reported no treatment-related dose-limiting toxic effects.
A phase 1a report described one-year durability of ANGPTL3 and lipid reductions after CTX310. The assessment notes that the abstract reported no treatment-related dose-limiting toxic effects. [C15]
What the result does not establish
Biomarker reductions do not establish fewer cardiovascular events or longer life. A small early-phase safety report is not a guarantee of long-term product safety.
Measured endpoint
ANGPTL3 and lipid biomarkers; early safety observations.
Karam’s next question
Which patient-relevant clinical outcomes remain untested, and what longer follow-up is required?
Assessment-derived brief. Cited in the supplied 15 October 2026 project assessment; not independently reviewed in this website release. Karam has not reproduced the experiment or independently audited the underlying dataset. This is not Karam-generated evidence.
Record transparency
The details—and the missing values.
Extraction scope: supplied project assessment, not an independent full-methods extraction
Study date
2026-08-28
Reported region
Not assigned
Species / biological system
Human
Target / subject
ANGPTL3
Cell or population context
Participants in an early-phase cardiovascular-risk program
Perturbation direction
Disease-related target editing
Method
In vivo CRISPR-Cas9
Delivery setting
Product-specific in vivo editing
Comparator
Not extracted in the supplied assessment; review the primary source before using this field.
Donor context
Not extracted in the supplied assessment; review the primary source before using this field.
Sample size / unit
Not extracted in the supplied assessment; review the primary source before using this field.
Follow-up
One-year durability as summarized in the assessment.
Safety measurements
Not extracted in the supplied assessment; review the primary source before using this field.
Independent replication
Not established in the supplied assessment
Data access
Not extracted in the supplied assessment; review the primary source before using this field.
What would this evidence change?
Use the context in this record to define a bounded research or diligence question. A cited finding is not a validated Karam asset.
